Top

The Journal of Obstetrics and Gynecology of India

Published in:

01-10-2016 | Original Article

A Prospective Study of Placental Growth Factor Assay as a Novel Biomarker in Predicting Early-Onset Preeclampsia in High-Risk Patients

Authors: Pooja Mathur, Poonam Mathur, Laxmi Maru, Anupama Dave

Published in: The Journal of Obstetrics and Gynecology of India | Special Issue 1/2016

Abstract

Introduction

Preeclampsia is a leading cause of maternal and perinatal mortality and morbidity, but signs and symptoms are non-specific and may vary. The root cause is imbalance of circulating angiogenic factors of placental (syncytiotrophoblast) origin, with consequent low levels of placental growth factor (PlGF) which may aid in diagnosis and prediction of disease.

Aims and Objectives

To study the incidence of women at risk of developing early-onset preeclampsia by plasma placental growth factor biomarker assay in high-risk patients, to assess the maternal outcome in patients with PlGF values below cutoff for presenting gestational age, to calculate sensitivity, specificity, positive predictive value and negative predictive value of PlGF assay in predicting preeclampsia and to conclude whether PlGF biomarker assay can be an effective screening test in high-risk patients for prediction of early-onset preeclampsia.

Materials and Methods

The study was carried out in the Department of Obstetrics and Gynecology at a tertiary care center. It is a prospective study, and study period extended from April 2012 to October 2013. One hundred pregnant women with 20- to 34-week gestational age with possible high risk of developing preeclampsia attending the antenatal clinics and high-risk OPDs were screened in the present study after explaining the nature of the study. PLGF concentration was quantitated using plasma and processed in Triage kit device (fluorescence immunoassay device). PLGF concentration was categorized against a specific range for specific gestation, and values below the range or <12 pg/ml were considered screened positives. The cases were followed up till delivery.

Results

Twenty-two cases were screened positive, of which 20 developed preeclampsia with a strong positive prediction value of more than 90 %.

Conclusion

PLGF is a strong predictor and a useful assay for early-onset preeclampsia.

Menzies J, Magee LA, Macnab YC, et al. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy. 2007;26:447–62.CrossRefPubMed

Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004;103:981–91.CrossRefPubMed

Magee LA, von Dadelszen P, Chan S, et al. The control of hypertension in pregnancy study pilot trial. BJOG. 2007;114:770.e13–20.CrossRef

Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013. doi:10.1161/CIRCULATIONAHA.113.003215.PubMed

Maynard S, Min J, Merchan J, et al. Excess placental soluble FMS-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–58.CrossRefPubMedPubMedCentral

Venkatesha A, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642–9.CrossRefPubMed

Levine R, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992–1005.CrossRefPubMed

Taylor R, Grimwood J, Taylor R, et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003;188:177–82.CrossRefPubMed

Buhimschi C, Norwitz E, Funai E, et al. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol. 2005;192:734–41.CrossRefPubMed

10.

Levine R, Maynard S, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–82.CrossRefPubMed

11.

Wikstrom A, Larsson A, Eriksson U, et al. Placental growth factor and soluble fms-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol. 2007;109:1368–74.CrossRefPubMed

12.

Romero R, Nien J, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational neonate. J Matern Fetal Neonatal Med. 2008;21:9–23.CrossRefPubMedPubMedCentral

13.

Ohkuchi A, Hirashima C, Matsubara S, et al. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res. 2007;30:151–9.CrossRefPubMed

14.

Benton SJ, Hu Y, Xie F, et al. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol. 2011;205:469.e1–8.CrossRef

15.

Sharon Maynard Annu. Rev. Med. 2008.59:61–78. Downloaded from arjournals.annualreviews.org by Mr Paul Sheard on 03/19/08.

16.

Triage^® PLGF Test Product Insert.2011.

17.

Sibai BM. Hypertension. In: Gabbe SG, Niebyl JR, Galen H, et al., editors. Obstetrics: Normal and problem pregnancies. 6th ed. New York: Elsevier; 2012. p. 779–822.CrossRef

18.

Hirashima C, Ohkuchi A, Arai F, et al. Establishing reference values for both total soluble Fms-like tyrosine kinase 1 and free placental growth factor in pregnant women. Hypertens Res. 2005;28:727–32.CrossRefPubMed

19.

Cnossen JS, ter Riet G, Mol BW, et al. Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal. Acta Obstet Gynecol Scand. 2009;88:758–65.CrossRefPubMed

20.

Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2009;201:e1–11.

21.

Knudsen UB, Kronbog CS, von Dadelszen P, et al. Pregnancy hypertension: an international Journal of Women’s Cardiovascular. Health. 2012;2:8–15.CrossRef

Title: A Prospective Study of Placental Growth Factor Assay as a Novel Biomarker in Predicting Early-Onset Preeclampsia in High-Risk Patients
Authors: Pooja Mathur
Poonam Mathur
Laxmi Maru
Anupama Dave
Publication date: 01-10-2016
Publisher: Springer India
Published in: The Journal of Obstetrics and Gynecology of India / Issue Special Issue 1/2016
Print ISSN: 0971-9202
Electronic ISSN: 0975-6434
DOI: https://doi.org/10.1007/s13224-015-0793-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

A Prospective Study of Placental Growth Factor Assay as a Novel Biomarker in Predicting Early-Onset Preeclampsia in High-Risk Patients

Abstract

Introduction

Aims and Objectives

Materials and Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Introduction

Aims and Objectives

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Special Issue 1/2016

Field Testing of Second Generation of Colour-Coded Rings for Detecting Slow Progress of Labour at Rural Health Centres

Ultrasonography and Doppler Study to Predict Uterine Receptivity in Infertile Patients Undergoing Embryo Transfer

Analysis of near-miss and maternal mortality at tertiary referral centre of rural India

An Overview on Fertility Outcome in Renal Transplant Recipients

Prevalence of Vitamin D Deficiency in Burka-clad Pregnant Women in a 450-Bedded Maternity Hospital of Delhi

Evaluation of Role of GnRH Antagonist in Intrauterine Insemination (IUI) Cycles with Mild Ovarian Hyperstimulation (MOH): A Prospective Randomised Study